Month: April 2020

CALGARY, Alberta, April 24, 2020 (GLOBE NEWSWIRE) — – News Release – TC Energy Corporation (TSX, NYSE: TRP) (TC Energy) announced today that its wholly-owned subsidiary, NOVA Gas Transmission Ltd. (NGTL), has reached a five-year negotiated revenue requirement settlement with its customers and other interested parties that extends from 2020 to 2024.“This settlement is the result of a collaborative engagement with our customers and is responsive to the needs of both the industry and our business,” said Russ Girling, TC Energy President and Chief Executive Officer. “Recognizing it is a challenging time for a number of our customers, this innovative settlement includes incentives to keep tolls competitive while providing a stable return to TC Energy as we execute in excess of $14 billion of pipeline projects to enhance the connectivity...

Special Meeting UpdateDonation of Personal Protective Equipment to St. Paul’s HospitalUpdated Timeline for Delivery of Winter 2020 Drill Program ResultsVANCOUVER, British Columbia, April 24, 2020 (GLOBE NEWSWIRE) — Balmoral Resources Ltd. (“Balmoral” or the “Company”) (TSX:BAR; OTCQX:BALMF) announced today that the two leading independent institutional proxy advisory firms, Institutional Shareholder Services  Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have each recommended that shareholders vote FOR the special resolution, as outlined in the Company’s management information circular (the “Circular”) (available on the Balmoral website under the Company’s profile at www.sedar.com), whereby Wallbridge Mining Company Limited (“Wallbridge”) will acquire all of the issued and outstanding shares of Balmoral under the terms...

NEW YORK and BASEL, Switzerland, April 24, 2020 (GLOBE NEWSWIRE) — Axovant Gene Therapies Ltd. a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it had prepaid in full its $15.7 million outstanding loan from Hercules Capital, Inc. together with interest, fees and other amounts due. Following the prepayment, the credit facility and loan agreement with Hercules Capital, Inc. was terminated, and all obligations, liens and security interests under the loan agreement were released, discharged and satisfied.“Axovant is debt-free after the loan prepayment announced today. This prepayment has no meaningful impact on our cash runway, removes prior liens by Hercules on our assets, and saves approximately $1 million in interest expense. Together with the $74.7 million equity financing...

SAN DIEGO and TORONTO, April 24, 2020 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, announced today that it has filed its proxy statement for the 2020 annual general meeting of shareholders.The annual general meeting of Aptose shareholders will be held on June 2, 2020 at 10:00 a.m. Pacific time in an online only format. There will be no physical location for shareholders and duly appointed proxyholders to attend. Aptose shareholders and duly appointed proxyholders may attend the virtual meeting online at https://web.lumiagm.com/192484056, where they will be able to listen, vote, and submit questions during the meeting’s live webcast. Detailed instructions for shareholders...

1Q 2020 highlightsConsolidated:$1.00 in earnings per share (EPS), compared with $1.22 in 1Q 2019; adjusted EPS (non-GAAP), excluding special items, of $1.26, compared with $1.20 in 1Q 2019.Operating revenue decline of 1.6 percent from first-quarter 2019.Cash flow from operations of $8.8 billion, an increase of $1.7 billion from first-quarter 2019.Consumer:Total revenue of $21.8 billion, a decrease of 1.7 percent year over year.525,000 retail postpaid net losses, including 307,000 phone net losses and 167,000 postpaid smartphone net losses.Total retail postpaid churn of 1.01 percent, and retail postpaid phone churn of 0.77 percent.59,000 Fios Internet net additions.Business:Total revenue of $7.7 billion, a decrease of 0.5 percent year over year.475,000 retail postpaid net additions, including 239,000 phone net additions.Total retail postpaid...

HOUSTON, April 24, 2020 (GLOBE NEWSWIRE) — Era Group Inc. (NYSE:ERA) (“Era”) announced today that on April 21, 2020 it repurchased an aggregate of 54,099 shares of its common stock at an average price of $3.64 per share, on April 22, 2020 it repurchased an aggregate of 46,027 shares of its common stock at an average price of $3.81 per share and on April 23, 2020 it repurchased an aggregate of 24,036 shares of its common stock at an average price of $4.23 per share under its previously announced special stock repurchase program, which allows for the purchase of up to $10 million of its common stock (the “Program”). All shares of common stock repurchased under the Program will be held as treasury shares. Following the repurchase of shares under the Program to date, Era will have 21,632,110 shares of common stock outstanding.The total...

Lima, April 24, 2020 (GLOBE NEWSWIRE) — Lima, April 23, 2020 – Credicorp Ltd. announces that the Board of Directors, in its session held on April 23rd, 2020, has agreed to schedule the Annual General Shareholders Meeting to take place on June 5th, 2020 at 3:00 pm. In order to protect the health and safety of our employees, shareholders and other stakeholders from the COVID-19 pandemic, Credicorp will hold the meeting virtually and there will be no in-person meeting this year. Shareholders registered as of May 6th will have the right to attend and vote at the meeting. Details of virtual meeting logistics will be provided shortly along with the Annual General Shareholders Meeting Notice.Credicorp postponed its Annual General Shareholders Meeting, originally scheduled to take place on March 27th, 2020, in order to prevent the transmission...

Selskabsmeddelelse nr. 26/2020| 24. april 2020Danske Andelskassers Bank A/S har i selskabsmeddelelse nr. 20/2020 den 6. april 2020 udsendt indkaldelse til generalforsamling den 29. april 2020.Under dagsordenens pkt. 8 b) stiller bestyrelsen forslag om en bemyndigelse til forhøjelse af bankens aktiekapital uden fortegningsret for de hidtidige aktionærer. Forslaget fastholdes, men bestyrelsen har besluttet at nedsætte størrelsen af bemyndigelsen, således at der alene anmodes om en bemyndigelse til at forhøje bankens aktiekapital med op til i alt nominelt kr. 74.364.924 svarende til 20% af bankens aktiekapital.Den fulde ordlyd af forslaget under dagsordenens pkt. 8 b) er herefter: Ad pkt. 8 b) Ændring af § 4a, stk. 2Bestyrelsen stiller forslag til ændring af bankens vedtægter, hvorved der indsættes en bemyndigelse til bestyrelsen til at gennemføre...

不列颠哥伦比亚省温哥华, April 24, 2020 (GLOBE NEWSWIRE) — 临床阶段药物开发企业Algernon Pharmaceuticals Inc.（CSE: AGN）（FRANKFURT: AGW）（OTCQB: AGNPF）（以下称“该公司”或“Algernon”）非常高兴地宣布，其再利用药物NP-120（艾芬地尔）（NMDA受体拮抗剂）的研究者主导的第二阶段新冠肺炎临床研究已获得韩国食品和药物安全部的批准，并已通过伦理审查。首席研究员是釜山市东亚大学医院传染病科教授Dong Sik Jung博士。此次对40名患者进行的为期4周的试验旨在测试艾芬地尔对出现严重肺炎症状的新冠病毒感染者的治疗效果。患者按1:1的比例随机分组，分别接受标准疗法（SOC）和采用艾芬地尔的SOC。主要测试指标将是通过测量血液含氧量（Pa02/Fi02）获知患者肺部功能提升的速度。次要测试指标包括死亡率、呼吸机使用率，以及患者反馈的针对咳嗽和呼吸困难症状的效果。参与第2阶段临床试验的注册预计将于2020年5月8日开始。“艾芬地尔用于新冠肺炎患者的首次人类试验是我们新的急性肺部损伤临床研究计划向前迈出的一大步”，Algernon首席执行官Christopher J. Moreau表示。“随着我们继续研究艾芬地尔针对新冠肺炎的治疗潜力，第2阶段的肯定性数据将是一个重要的里程碑；此外，这也将推进我们的特发性肺纤维化和慢性咳嗽研究计划。”该公司提示，虽然公司正准备于近期在韩国开始第二阶段临床试验，但并没有对NP-120（艾芬地尔）作为急性肺部损伤（ALI）、新冠肺炎病毒或任何其他疾病的有效疗法做出任何明示或暗示的声明。关于NP-120（艾芬地尔）NP-120（艾芬地尔）是一种N-甲基-d-天冬氨酸（NDMA）受体拮抗剂，专门针对NMDA型亚基2B（Glu2NB）。艾芬地尔可阻止谷氨酸信号传导。肺部细胞和T细胞、中性粒细胞等许多组织中都有NMDA受体。该公司认为NP-120可以减少中性粒细胞和T细胞浸润到肺中，而这两种细胞在肺部可分别释放谷氨酸和细胞因子。后者可能导致非常严重的细胞因子风暴，致使肺部功能丧失，并最终导致死亡，正如报告的新冠病毒感染者所出现的情况。关于Algernon...